European Medicines Agency recommends granting a conditional marketing authorisation for cabozantinib for the treatment of medullary thyroid cancer

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product cabozantinib (Cometriq) 20 mg and 80 mg hard capsules, intended for the treatment of medullary thyroid cancer, a rare type of thyroid cancer, that cannot be removed by surgery or that has spread to other parts of the body. Read more here.